Aims/hypothesis Pre-adipocytes and adipocytes are responsive to the acute phase protein serum amyloid A (SAA). The combined effects triggered by SAA encompass an increase in preadipocyte proliferation, an induction of TNF-α and IL-6 release and a decrease in glucose uptake in mature adipocytes, strongly supporting a role for SAA in obesity and related comorbidities. This study addressed whether SAA depletion modulates weight gain and insulin resistance induced by a high-fat diet (HFD). Methods Male Swiss Webster mice were fed an HFD for 10 weeks under an SAA-targeted antisense oligonucleotide (ASO SAA ) treatment in order to evaluate the role of SAA in weight gain. Results With ASO SAA treatment, mice receiving an HFD did not differ in energy intake when compared with their controls, but were prevented from gaining weight and developing insulin resistance. The phenotype was characterised by a lack of adipose tissue expansion, with low accumulation of epididymal, retroperitoneal and subcutaneous fat content and decreased inflammatory markers, such as SAA3 and toll-like receptor (TLR)-4 expression, as well as macrophage infiltration into the adipose tissue. Furthermore, a metabolic status similar to chow-fed mice counterparts could be observed, with equivalent levels of leptin, adiponectin, IGF-I, SAA, fasting glucose and insulin, and remarkable improvement in glucose and insulin tolerance test profiles. Surprisingly, the expected HFD-induced metabolic endotoxaemia was also prevented by the ASO SAA treatment.
Introduction
Chronic and low-grade inflammation is a hallmark of obesity and a key factor for the development of obesity comorbidities [1] . More than simply a consequence of obesity, low-grade chronic inflammation, especially that triggered by the endotoxaemia derived from intestinal microbiota, has been identified as a cause of weight gain, obesity and insulin resistance [2, 3] . Indeed, high-fat feeding modulates gut microbiota and the plasma concentration of endotoxin, correlating to the occurrence of metabolic diseases [3] .
One point addressed in this study was the identification of additional factors linking endotoxaemia and weight gain. Biochemical changes favouring obesity include cytokines and several inflammatory factors, as well as the involvement of toll-like receptors (TLRs) [4, 5] . Herein, we addressed whether serum amyloid A (SAA), an acute phase protein and TLR ligand, links inflammation to the onset of weight gain and comorbidities.
In mice, three functional and distinct inducible isoforms of SAA have been identified, SAA1.1, SAA2.1 and SAA3 [6, 7] . In response to a proinflammatory stimulus, the liver produces the isoforms 1.1 and 2.1, while SAA3 is mainly expressed in extrahepatic tissues [8] [9] [10] . More specifically, SAA3 does not contribute to circulating levels of SAA and has been related mostly to the promotion of local inflammation [9, 11, 12] .
However, liver-derived SAA has been implicated not only in the regulation of inflammatory responses [13] [14] [15] but also in the control of cell proliferation [16] [17] [18] and metabolic profile [18] [19] [20] . Although mainly secreted by the liver, SAA has also been reported as being produced by adipocytes, macrophages and several other cell types [21, 22] , with levels positively correlated with obesity grade, as well as increased expression under hypoxic conditions [22, 23] .
SAA is an endogenous ligand to TLR-4 [13] and TLR-2 [24] and was recently described as causing impairment to the scavenger receptor BI (SR-BI) [20] . All these receptors are admittedly associated with the inflammatory response and also related to lipopolysaccharide (LPS) responsiveness [13, 24, 25] .
In order to evaluate the role of SAA in weight gain, SAAtargeted antisense oligonucleotide (ASO SAA ) was used in a high-fat diet (HFD)-induced experimental model of obesity. Although metabolic endotoxaemia is considered one of the early factors in HFD-induced metabolic diseases [2] , in this study we identified SAA as an additional trigger driving weight gain and insulin resistance.
Methods
Animals Male Swiss Webster mice (21 days of age) were obtained from the Animal Facility at the Faculty of Pharmaceutical Sciences, University of São Paulo, Brazil, under approval by its ethics committee (number 297) and in accordance with international guidelines on animal experimentation. The animals were housed inside standard polypropylene cages in a room maintained at 22 ± 2°C with a 12:12 h light/dark cycle (lights on at 07:00 hours and off at 19:00 hours) and 55 ± 10% relative humidity. Body weight was measured once a week during the entire protocol. Food and water intake were ad libitum and measured every 2 days. No death was recorded and no mice were dropped out of the analysis during the course of the experimental protocol. Euthanasia occurred by anaesthesia overdose (i.p. administration of a combination of ketamine [100 mg/kg] and xylazine [15 mg/kg]), and ensured by cervical dislocation.
Diet-induced obesity protocol and SAA depletion The experiments were performed using a custom-designed diet. The chow diet was produced following the American Institute of Nutrition recommendations AIN-93M (total energy: 75.8% carbohydrate, 9.3% fat and 14.9% protein) [26] , while the HFD group received an AIN-93M-based diet that was enriched with lard (total energy: 24.2% carbohydrate, 60.9% fat and 14.9% protein) [27] . The diet composition is listed in Table 1 . For the experimental protocol, mice were first randomly assigned to two different groups in order to receive chow or the HFD for 10 weeks. Each group was then split again to receive antisense oligonucleotide in vivo treatment for Saa mRNA inhibition (kindly provided by Ionis Pharmaceuticals, Carlsbad, CA, USA). The following groups were formed: control (no antisense oligonucleotide [ASO] treatment), ASO not specific to any murine transcript (ASO scramble ) and ASO SAA (specific for the murine Saa1 and Saa2 transcripts). Both ASOs are based on generation 2.5 chemistry, which consisted of 2-O, 4-C-[(S)-ethylidene]-D-ribose ('cEt') modified sugars for the three terminal 5′ and 3′ nucleotides that flank a central ten-nucleotide DNA gap [28] . The ASO treatment was performed via i.p. administration at a dose of 25 mg/kg of the animal, once a week. The ASO sequences and chemistries are listed in Table 2 .
Glucose and insulin tolerance tests and measurements of serum leptin, adiponectin, insulin, IGF-I, SAA and endotoxin Glucose and insulin tolerance tests (GTTs and ITTs) were performed as described previously [29] . Serum concentrations Histological analysis Paraffin-embedded sections (5 μm thick) from epididymal adipose tissue were stained with haematoxylin and eosin in order to assess morphology.
Immunofluorescence for F4/80 (macrophage identification), SAA and perilipin (a marker of lipid droplet structures, also useful to identify crown-like structures) was performed using a rat anti-mouse F4/80 antibody and rabbit anti-mouse perilipin (both at 1:100 dilution; Abcam, Cambridge, UK, catalogue numbers ab6640 and ab3526), and a rabbit antimouse SAA (1:200 dilution, kindly provided by the de Beer laboratory, University of Kentucky, Lexington, KY, USA). They were subsequently incubated with the appropriate secondary fluorescent antibody (Invitrogen, Camarillo, CA, USA) and the slides mounted using Vectashield set mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA, catalogue number H-1200) for nuclei staining. An isotype control was used to ensure antibody specificity in each staining (data not shown). Tissue sections were observed with a Nikon Eclipse 80i microscope (Nikon, Melville, NY, USA), and digital images were captured with NIS-Element AR software (Nikon).
In vivo peripheral fat area quantification Two x-ray images were taken at different energy levels, thus allowing us to circumscribe the adipose tissue on the animals as described previously [29] .
Quantitative real-time PCR Total RNA from epididymal adipose tissue was isolated using Qiagen RNeasy Lipid Tissue Mini kit (Qiagen, Hilden, Germany, catalogue number 74804). cDNA was synthesised from 1 μg of RNA using the High Capacity cDNA Reverse Transcription kit (Life Technologies, Grand Island, NY, USA, catalogue number 4368814). Real-time PCR was performed using SyBr Green Master Mix (Life Technologies, catalogue number 4309155). The primer sequences are detailed in Table 3 . Real-time PCR for Saa3 was performed using the TaqMan assay (Applied Biosystems, Grand Island, NJ, USA, catalogue number Mm00441203_m1), with β-actin (ACTB) (catalogue number 4552933E) as an endogenous housekeeping gene control. Relative gene expression was determined using the 2 −ΔΔC t method [30] .
Statistical analysis Results are presented as mean ± SEM. Statistical analysis was performed with Graph Pad Prism4 (Graph Pad Software, San Diego, CA, USA). Data with two independent factors were tested by two-way analysis of variance (two-way ANOVA, a parametric test), followed by Bonferroni post hoc test. The level of significance was set at p < 0.05.
Results
SAA depletion prevents weight gain induced by HFD In order to address the involvement of the SAA protein in weight Tlr2 (TLR2) 5′-CAG CTG GAG AAC TCT GAC CC-3′ 5′-CAA AGA GCC TGA AGT GGG AG-3′
Tlr4 (TLR4) 5′-TCA TGG CAC TGT TCT TCT CCT-3′ 5′-CAT CAG GGA CTT TGC TGA GTT-3′ Cd14 (CD14) 5′-GCG AGC TAG ACG AGG AAA GT-3′ 5′-CAC GCT TTA GAA GGT ATT CCA G-3′
Gapdh (GAPDH) 5′-TGG CAA AGT GGA GAT TGT TGC C-3′ 5′-AAG ATG GTG ATG GGC TTC CCG-3′
GAPDH, glyceraldehyde-3-phosphate dehydrogenase gain and insulin resistance, mice fed a chow diet or HFD for 10 weeks and concurrently subjected to ASO SAA administration were analysed regarding adipose tissue composition and architecture. SAA levels tend to increase when an HFD is introduced, but the ASO SAA mRNA inhibitor was effective in decreasing the serum concentration of SAA in mice receiving the HFD (Table 4) . Considering the type of diet used, no effect was observed on the energy intake when ASO scramble or ASO SAA were administered (Fig. 1a) . The growth curves for mice fed a chow diet did not show any developmental differences from control, ASO scramble or ASO SAA groups, demonstrating no toxic or side effects from the ASO treatment (Fig. 1b) . However, the ASO SAA group was protected from the effects of the HFD. Moreover, the growth curve, the visceral fat depot and subcutaneous fat depot weight were comparable with those of a chow diet-fed animal (Fig. 1c-f) . These data were confirmed using x-ray images highlighting the subcutaneous fat area, showing that HFD + ASO SAA mice have a minor peripheral fat area when compared with HFD or HFD + ASO scramble mice (Fig. 1g, h ).
SAA depletion prevents HFD-induced adipose tissue expansion and macrophage infiltration into the adipose tissue After 10 weeks on an HFD, it was possible to identify several crown-like structures, defined as a perilipin-free adipocyte surrounded by macrophage (F4/80 + ), in the adipose tissue from control and ASO scramble mice (Fig. 2,  middle column) . Moreover, the HFD significantly increased the staining for SAA in the adipose tissue in control and ASO scramble mice (Fig. 2, right column) . When mice receiving the HFD were concomitantly treated with ASO SAA , no significant staining for F4/80 and SAA was observed (Fig. 2, middle and right column) , indicating the absence of both macrophage infiltration and local inflammation. Furthermore, ASO SAA treatment also prevented adipocyte hypertrophy, demonstrating the involvement of SAA in adipose tissue expansion and remodelling (Fig. 2, left column and Fig. 3a) . These effects derived from SAA depletion were not observed in chowfed mice (Fig. 2 , middle and right column).
SAA depletion prevents the metabolic imbalance induced by an HFD The metabolic status of the animals treated with ASO SAA was also assessed. Remarkably, endotoxin levels from mice treated with ASO SAA under an HFD were comparable with those from a chow-fed animal (Fig. 3b) . Moreover, the trend to maintain the metabolic balance is clear, as no changes were observed in serum levels of leptin (Fig. 3c) , adiponectin (Fig. 3d) , IGF-I (Fig. 3e) , SAA (Fig. 3f) , fasting glucose (Fig. 3g) or insulin (Fig. 3h) . Thus, treatment with ASO SAA enables an improvement in glucose tolerance and insulin resistance, notably affected when an HFD is introduced ( Fig. 3i-n) . As expected, an HFD resulted in an increase in some of the inflammatory markers (Saa3 [ Fig. 3p] and Tlr4 [ Fig. 3r]) ; however, no changes in Saa1/2 (Fig. 3o) , Tlr2 (Fig. 3q) or Cd14 (Fig. 3s) were observed. Interestingly, SAA depletion also prevented the elevation of Saa3 and Tlr4 expression in adipose tissue from mice receiving an HFD (Fig. 3p , r, respectively).
Discussion
In order to define the contribution of SAA in obesity, the effect of SAA depletion in a diet-induced obesity protocol using ASO SAA was evaluated. Under an HFD, the serum levels of SAA doubled; ASO SAA treatment efficiently reduced SAA to its basal level. The treatment with ASO SAA was characterised by a striking reduction of deleterious alterations caused by an HFD, underlying the importance of SAA in obesity. The role of SAA in adipose tissue began to be unravelled in recent years with a number of in vitro studies. When not associated with HDL, SAA is a stimulus for the production of cytokines, reactive oxygen species and NO [13] [14] [15] 31] . SAA is also able to activate the inflammasome pathway, considered a mediator of the innate and adaptive immune system [32, 33] . Furthermore, SAA is induced by hypoxia [22] , a common event in fat expansion. Its production may affect adipose tissue homeostasis, such as inducing pre-adipocyte proliferation and inhibiting adipocyte glucose uptake [14, 17, 18, 31, 34] . SAA also induces lipolysis through an extracellular signalregulated kinase (ERK)-dependent pathway [35] and, despite the fact that lipolysis results in a decrease in adiposity, it also contributes to an elevation of circulating levels of NEFA, which impair glucose uptake by muscle and hepatic cells found in metabolic disorders [36] .
Also, the fact that neutrophils and monocytes of diabetic patients are more responsive to SAA regarding cytokine production and cell migration [37] further strengthens the need to study the potential effect of SAA in obesity and insulin resistance. Increased levels of SAA may contribute to a sustained accumulation and activation of inflammatory cells, as well as to the vascular complications observed in diabetic patients [37] . Although no receptor dedicated solely to SAA has yet been identified, SAA can bind and activate several cell surface receptors, including TLR-4 and TLR-2 [13, 23] , both of which have known roles in the development of obesity. For instance, the activation of TLR-4 and its co-receptor cluster of differentiation 14 (CD14) is associated with obesity and insulin resistance in a diet-induced obesity protocol in mice [2, 38, 39] .
The molecular mechanisms involving the activation of TLRs are associated with endoplasmic reticulum stress and activation of the c-Jun N-terminal protein kinases (JKNs) both in liver and in fat tissue, all associated with the promotion of inflammation [4, 39] .
It is also important to consider the complex interplay that leads to the production of SAA. It has been shown that adipocytes stimulated by recombinant human (rh)SAA increase the expression of SAA3 [18, 35] . In this panorama, not only the HFD may act in the adipose tissue driving the production of SAA3, but also the elevation of SAA1.1 and SAA2.2 in plasma would stimulate SAA3 expression in adipose tissue [9] . The interplay of SAA isoforms could be the reason for the reduction in SAA3 expression in the adipose tissue of mice submitted to an HFD under ASO SAA treatment.
This study, in an in vivo approach, confirms the expected beneficial effect of SAA depletion on weight gain and its comorbidities. It is important to highlight that although no evidence was found for a role of SAA in the development of obesity and insulin resistance in a transgenic mouse model expressing human SAA1 in the adipose tissue [40] , a recent study with Saa-knockout mice for isoform 3 showed an attenuated weight gain and macrophage infiltration into the adipose tissue after an obesogenic diet [41] . It is interesting to note that these effects were exclusive for female knockout mice. Moreover, Saa-knockout mice lacking SAA1.1 and SAA2.1 gained less weight when compared with their wild-type counterparts during their lifespan [42] . Taken together, the studies with Saa-knockout mice and the data presented herein with ASO SAA consolidate the participation of SAA in obesity through complementary experimental strategies.
Moreover, in an unprecedented manner, this study correlates SAA with metabolic endotoxaemia. It has found that ASO SAA prevented the elevation of endotoxin levels in serum, an increase that is expected when mice are submitted to an HFD. Changes observed in endotoxaemia levels under the ASO SAA treatment may be due to the effects of SAA on gut permeability or on LPS clearance. SAA is produced by colonic epithelium in response to the gut microbiota [11] and it is expected that inflammatory mediators cause an increase in gut permeability [43] , and therefore, endotoxaemia. After reaching the blood stream, virtually all LPS molecules are rapidly complexed with circulating proteins and lipoproteins. When complexed with HDL [44] , LPS is cleared by SR-BI in hepatocytes [45] and in other cell types such as macrophages and monocytes, as recently described [46] . The clearance of LPS through SR-BI efficiently determines the magnitude of the inflammatory response, and it has already been shown that SAA is associated with impairment of SR-BI [20] . Thus, the authors suggest that the reduction in SAA serum levels due to the ASO SAA treatment could decrease gut permeability to LPS and also improve SR-BI-mediated LPS clearance, leading to decreased endotoxaemia. Figure 4 summarises the main findings of the authors' previous [18] and current study outlining the possible relationship between LPS and SAA as factors driving obesity. The present study does not claim it has exhausted the subject and future studies should be addressed in order to fully unveil the mechanism underlying the role of SAA in diet-induced obesity. Accordingly, the authors think the focus should be on intestinal permeability and also on neuronal control of energy homeostasis, as hypothalamic injury and the activation of inflammatory signalling are associated with obesity in both rodents and humans [47] . Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
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